Judge rules J&J and Janssen misled physicians
Pharma Compliance Alert, March 11, 2009
Johnson & Johnson and its Janssen Pharmaceuticals unit must pay West Virginia roughly $4.5 million for misleading the state’s physicians about the risks and benefits of the antipsychotic Risperdal and narcotic pain patch Duragesic, according to a release from State Attorney General Darrell McGraw.
In his decision, West Virginia Circuit Court Judge Martin Gaughan noted the FDA issued warning letters to the companies for their promotion of Risperdal and Duragesic.
Read more about Gaughan's decision against J&J and Janssen.
Related Products
Most Popular
- Articles
-
- HIPAA Q&A: Flu shot requirement for hospital employees
- Running an effective peer review committee meeting
- HealthDataInsights posts new issues for medical necessity claims
- Sneak Peek: Effort underway to establish caseload benchmarks
- New FAQ posted on storing laryngoscope blades
- Q/A: Coding for telescopic intraocular lens
- Tip: Perform your own internal investigation prior to government audit
- HIPAA 5010 deadline extended, but threat remains, says AMA
- HHS task force: Consider privacy, security with text messages
- What does case-mix index mean to you?
- E-mailed
-
- Running an effective peer review committee meeting
- HIPAA Q&A: Flu shot requirement for hospital employees
- What does case-mix index mean to you?
- HHS task force: Consider privacy, security with text messages
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Q/A: Coding for telescopic intraocular lens
- Q/A: Correct use of modifier -PT
- Tip: Correctly code bilateral pain management procedures
- "Wall fountains" may be spreading Legionnaires to patients, visitors
- 2012 CPT code changes for ASCs: Shoulder and knee scopes and pain management
- Searched
